Free tool
FAERS Monitor: Beleodaq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206256 or its brand name (Beleodaq, Belinostat). Reports on generic versions are filed under their own applications.
Reports
358
Serious
318
89% of reports
Hospitalization
158
Death reported
121
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression77
- nausea59
- anaemia49
- death43
- vomiting43
- dyspnoea36
- platelet count decreased33
- fatigue32
- constipation28
- neutropenia26
- diarrhoea25
- white blood cell count decreased24
- neutrophil count decreased23
- pyrexia22
- pneumonia19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 10 |
| 2015 | 12 |
| 2016 | 5 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 12 |
| 2020 | 14 |
| 2021 | 70 |
| 2022 | 49 |
| 2023 | 57 |
| 2024 | 40 |
| 2025 | 48 |
| 2026 | 25 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,801 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 77 | 38.3 | 31.4 | 2,770 |
| neutrophil count decreasedSignal | 23 | 33.2 | 22.3 | 687 |
| platelet count decreasedSignal | 33 | 18.2 | 13.1 | 522 |
| anaemiaSignal | 49 | 15.1 | 11.6 | 637 |
| white blood cell count decreasedSignal | 24 | 13.0 | 8.8 | 255 |
| neutropeniaSignal | 26 | 11.2 | 7.8 | 234 |
| constipationSignal | 28 | 7.5 | 5.3 | 154 |
| vomitingSignal | 43 | 5.4 | 4.1 | 152 |
| nauseaSignal | 59 | 4.4 | 3.5 | 156 |
| dyspnoeaSignal | 36 | 3.7 | 2.7 | 71 |
| pyrexiaSignal | 22 | 3.7 | 2.5 | 42 |
| pneumoniaSignal | 19 | 3.4 | 2.2 | 31 |
| deathSignal | 43 | 2.9 | 2.2 | 55 |
| fatigueSignal | 32 | 2.4 | 1.7 | 26 |
| diarrhoeaSignal | 25 | 2.3 | 1.6 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.